Replies to post #243998 on Biotech Values

[LongRun8]

100% agreed. It's annoying when they use it as a verb like you described as opposed to using it for financial definitions you listed above. No worries about being pedantic; that's my style, too!

[IanFromSI]

Replying to a message of yours that was removed before I finished this response.


===============================


Everyone on this board knows exactly what I think about companies that still attack amyloid beta whether it’s a protein or a plaque.

I suspect the FDA is a little gun shy about approving another useless AD treatment.

I would be surprised if any company ever gets any funding from CMS or any other healthcare provider for treatment based on the “attack amyloid beta” philosophy.

I’ve given up hoping that big Pharma or most biotechs will ever focus on finding actual cures for AD.

It takes two successful PHIII’s for the FDA to approve a new drug. Why after several dozen failed phase 3’s does big Pharma and biotech continue to go after this ridiculous approach to treating Alzheimer’s?

Those companies have got some of the most brilliant researchers in the world. Even with all the sunk costs on the failed
amyloid beta approach I fail to understand why they keep trying to beat this dead horse.

Even though I’ve given up, I still hope that they’ll do the right thing. Their companies the patients families of the patients everybody will benefit from such a change.

I’ll probably not comment on those companies that believe in continuing with utter futility.

FWIW,

Ian